Rifalazil
Rifalazil Uses, Dosage, Side Effects, Food Interaction and all others data.
Rifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.
Rifalazil represents a new generation of ansamycins that contain a unique four-ring structure. Originally rifalazil was developed as a therapeutic agent to replace rifampin as part of a multiple drug regimen in the treatment of tuberculosis. As a result of its superior antimicrobial activity and high intracellular levels, rifalazil has potential to treat indications caused by the intracellular pathogen, Chlamydia trachomatis, which causes non-gonococcal urethritis and cervicitis, often leading to pelvic inflammatory disease. Rifalazil also has potential to treat the related microorganism, Chlamydia pneumoniae, which may be involved in chronic inflammatory processes thought to be partly responsible for atherosclerosis. Due to its favourable antimicrobial spectrum and other positive attributes, rifalazil may also prove valuable in the treatment of gastric ulcer disease, caused by Helicobacter pylori, and antibiotic-associated colitis, the result of toxin production following the growth of Clostridium difficile in the colon. The potential value of rifalazil in the treatment of these indications will be assessed in human clinical trials.
| Trade Name | Rifalazil |
| Generic | Rifalazil |
| Rifalazil Other Names | Rifalazil, Rifalazilo, Rifalazilum |
| Type | |
| Formula | C51H64N4O13 |
| Weight | Average: 941.088 Monoisotopic: 940.446988137 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in atherosclerosis, bacterial infection, and peripheral vascular disease.
How Rifalazil works
The potent antimycobacterial activity of rifalazil is due to inhibition of bacterial RNA polymerase.
Innovators Monograph
You find simplified version here Rifalazil
